|

Acoramidis Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AG10, ALXN2060

Pipeline

Phase 3: 1

Top Sponsors

  • Eidos Therapeutics, a BridgeBio company1

Indications

  • Transthyretin Amyloidosis1
  • Amyloid Cardiomyopathy1
  • Alzheimer's Disease1
  • Heart Disease1
  • Polyneuropathies1

La Jolla, California1 trial

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

University of California, San Diego (UCSD) - Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.